Kontafarma China
Kontafarma China, officially known as Kontafarma Limited, is a prominent player in the pharmaceutical and healthcare industry, headquartered in Hong Kong. Founded in 2005, the company has established a strong presence across Asia, focusing on the development and distribution of innovative healthcare solutions. Specialising in prescription medications, over-the-counter products, and health supplements, Kontafarma is recognised for its commitment to quality and efficacy. The company’s unique approach combines advanced research with a deep understanding of local market needs, allowing it to deliver tailored solutions that enhance patient care. With a reputation for excellence, Kontafarma has achieved significant milestones, including strategic partnerships and a growing portfolio of proprietary products. As a trusted name in the industry, Kontafarma continues to strengthen its market position, contributing to the advancement of healthcare in the region.
DitchCarbon Score
How does Kontafarma China's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kontafarma China's score of 53 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Kontafarma China's reported carbon emissions
Kontafarma China, headquartered in Hong Kong, has made significant strides in reducing its carbon emissions over recent years. In 2023, the company reported total emissions of approximately 1,783,000 kg CO2e, with Scope 1 emissions at about 1,057,000 kg CO2e and Scope 2 emissions at around 727,000 kg CO2e. This marks a notable decrease from 2021, when total emissions were approximately 10,000,000 kg CO2e, with Scope 1 emissions at about 4,034,000 kg CO2e and Scope 2 emissions at around 5,739,000 kg CO2e. The company has demonstrated a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been disclosed. The emissions data indicates a trend of decreasing emissions, particularly in Scope 1 and Scope 2 categories, suggesting ongoing efforts to enhance energy efficiency and reduce direct emissions from operations. Overall, Kontafarma China's emissions data reflects a proactive approach to climate commitments, aligning with industry standards for sustainability and carbon management.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2017 | 2018 | 2019 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 1,543,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 189,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 |
| Scope 3 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kontafarma China is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
